Delhi HC restricts supply of Zydus cancer drug Ikra in patent dispute

Litigation LossRegulatory & LegalExplain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹1133.80

prior close

₹1145.10

announcement price

After-mkt

timing

Nifty 100market+0.2%+2.2% vs market

Pharmaceuticals peers, median of 165sector+0.0%+2.4% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty 100 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.8

15m

-0.6

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.2+2.2+0.0+2.4

Next day

+1.5+0.1+1.4+0.0+1.5

+0.9+1.0-0.1-1.1+2.0

+1.3+0.8+0.5-0.5+1.8

+1.1+0.7+0.4-0.4+1.4

-0.8-0.1-0.7-1.7+0.9

-2.1-1.0-1.1-2.6+0.5

15d

-1.1+2.6-3.7-1.2+0.1

-0.2+1.5-1.7-0.5+0.3

-3.1-3.6+0.5-0.3-2.8

+0.6-4.4+5.0-2.3+2.9

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Delhi High Court has temporarily restricted Zydus Lifesciences from supplying its cancer drug Ikra amid a patent dispute with AbbVie. The stock exchange has sought clarification from the company on this news development. The company response is awaited. The restriction is interim and linked to alleged patent infringement claims filed by AbbVie against the product.

Likely market impact

Negative near-term - court order limits sales of cancer drug Ikra until the patent dispute with AbbVie is resolved.